ID   OSMR_RAT                Reviewed;         962 AA.
AC   Q65Z14;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2004, sequence version 1.
DT   24-JUL-2024, entry version 106.
DE   RecName: Full=Oncostatin-M-specific receptor subunit beta;
DE   AltName: Full=Interleukin-31 receptor subunit beta;
DE            Short=IL-31 receptor subunit beta;
DE            Short=IL-31R subunit beta;
DE            Short=IL-31R-beta;
DE            Short=IL-31RB;
DE   Flags: Precursor;
GN   Name=Osmr; Synonyms=Osmrb;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15743783; DOI=10.1016/s0002-9440(10)62292-4;
RA   Okaya A., Kitanaka J., Kitanaka N., Satake M., Kim Y., Terada K.,
RA   Sugiyama T., Takemura M., Fujimoto J., Terada N., Miyajima A.,
RA   Tsujimura T.;
RT   "Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing
RT   differentiation into hepatocytes.";
RL   Am. J. Pathol. 166:709-719(2005).
CC   -!- FUNCTION: Associates with IL31RA to form the IL31 receptor. Binds IL31
CC       and activates STAT1, STAT3 and STAT5. Capable of transducing OSM-
CC       specific signaling events (By similarity). The OSM/OSM-R system is
CC       pivotal in the differentiation of oval cells into hepatocytes, thereby
CC       promoting liver regeneration. {ECO:0000250,
CC       ECO:0000269|PubMed:15743783}.
CC   -!- SUBUNIT: Heterodimer composed of OSMR and IL6ST (type II OSM receptor).
CC       Heterodimer with IL31RA to form the IL31 receptor (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Single-pass type I
CC       membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed at high levels in the
CC       liver, skin and spleen. In the liver it is expressed exclusively in the
CC       oval cells. {ECO:0000269|PubMed:15743783}.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-surface
CC       receptor binding. {ECO:0000250}.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 2
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB167522; BAD44758.1; -; mRNA.
DR   RefSeq; NP_001005384.1; NM_001005384.1.
DR   AlphaFoldDB; Q65Z14; -.
DR   SMR; Q65Z14; -.
DR   STRING; 10116.ENSRNOP00000039644; -.
DR   GlyCosmos; Q65Z14; 5 sites, No reported glycans.
DR   GlyGen; Q65Z14; 5 sites.
DR   PhosphoSitePlus; Q65Z14; -.
DR   SwissPalm; Q65Z14; -.
DR   PaxDb; 10116-ENSRNOP00000039644; -.
DR   GeneID; 310132; -.
DR   KEGG; rno:310132; -.
DR   UCSC; RGD:1302983; rat.
DR   AGR; RGD:1302983; -.
DR   CTD; 9180; -.
DR   RGD; 1302983; Osmr.
DR   eggNOG; ENOG502QWRV; Eukaryota.
DR   InParanoid; Q65Z14; -.
DR   OrthoDB; 5347052at2759; -.
DR   PhylomeDB; Q65Z14; -.
DR   Reactome; R-RNO-6788467; IL-6-type cytokine receptor ligand interactions.
DR   PRO; PR:Q65Z14; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0016324; C:apical plasma membrane; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0005900; C:oncostatin-M receptor complex; ISO:RGD.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005127; F:ciliary neurotrophic factor receptor binding; IBA:GO_Central.
DR   GO; GO:0019955; F:cytokine binding; ISO:RGD.
DR   GO; GO:0004896; F:cytokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019838; F:growth factor binding; ISO:RGD.
DR   GO; GO:0004924; F:oncostatin-M receptor activity; ISO:RGD.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0038165; P:oncostatin-M-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0034097; P:response to cytokine; ISO:RGD.
DR   CDD; cd00063; FN3; 3.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 7.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR003529; Hematopoietin_rcpt_Gp130_CS.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR048497; LIF-R-like_Ig-like.
DR   InterPro; IPR040817; LIFR_D2.
DR   InterPro; IPR050379; Type-I_Cytokine_Rcpt.
DR   PANTHER; PTHR23036; CYTOKINE RECEPTOR; 1.
DR   PANTHER; PTHR23036:SF95; ONCOSTATIN-M-SPECIFIC RECEPTOR SUBUNIT BETA; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF21177; LIF-R_Ig-like; 1.
DR   Pfam; PF17971; LIFR_D2; 1.
DR   SMART; SM00060; FN3; 5.
DR   SUPFAM; SSF49265; Fibronectin type III; 3.
DR   PROSITE; PS50853; FN3; 5.
DR   PROSITE; PS01353; HEMATOPO_REC_L_F2; 1.
PE   2: Evidence at transcript level;
KW   Disulfide bond; Glycoprotein; Membrane; Receptor; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..28
FT                   /evidence="ECO:0000255"
FT   CHAIN           29..962
FT                   /note="Oncostatin-M-specific receptor subunit beta"
FT                   /id="PRO_0000259761"
FT   TOPO_DOM        29..738
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        739..759
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        760..962
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          237..332
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          333..426
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          428..527
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          528..621
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          623..734
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   REGION          818..840
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           413..417
FT                   /note="WSXWS motif"
FT                   /evidence="ECO:0000250"
FT   MOTIF           768..776
FT                   /note="Box 1 motif"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        219
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        324
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        492
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        578
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        723
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        243..253
FT                   /evidence="ECO:0000250"
SQ   SEQUENCE   962 AA;  108625 MW;  A7A15FED59A6E21A CRC64;
     MAFSVVLHQV TFLLAVLSLR TSQSKVLGEP LQLTPEIHTV SLQSALQEAN LEWTVPTFSH
     QELNIVFQIE ISRMRTSNTI WVGNYSTTVK HEETVHWKWT SDIPLECATH FIRIRAMVDD
     AQYPPQSSWS NWSSWKEVNA QVSVPPDTLL IFPEDRLLEE GSNVTICLMI GQNLYNVSCK
     LQEEPIRGEQ LDSHLSLIKL NNVVFLNNAG TNINCKAMNG TKNTFGTVLF VSKVLEEPKN
     FSCETRDFKT LNCLWEPGID TTLSWHKQRS QHYTLYESFS GRREVSNHRN SHTWQITEDS
     QETYNFTLTA ENNLRKRSVS ISFNLTHRVH PKAPHDVTLK TVGATKAHMT WKVPSRGDYT
     LLCQVELQCE GEVIHEHNVS VHTSANYLFS DLEPDTEYKA CVRCASANHF WKWSDWMQKK
     FRTPEAAPSE ALDVWRDVRT ENGRHVVTLF WKPLLKSQAN GKIISYNIVV ENEANPTESE
     QYSVRAPALG TNLSLDLHPY KIHISANNSA GASPESLVVL SSHSGHEEVH EKTIKGIKNG
     FNISWEPVSG DAIGYVVDWC AHSQTQRCDL QWKNVGPNIT STIITSDAFE PGVRYNFRIF
     ERSVEENVRL VEKQRGYTQE LAPSVNPGVT IHNLTPNSFS LKWQDYASDF QSGFIKGYLV
     YLKSKELQCN PNWERTVLSD KSVLCKYDVD DPETKTLTVE NLRPESLYEF LVTPYTSAGQ
     GPNETYTKVT TPDVRSHMLL QIILPMTLGV FLSIIVCYWK SQWVKEKCYP DIPNPYKSSI
     LSLIKSKKNP HLIMNVKDCI PDVLEVINKA EGSKTQCVGS GKLHTEDVPT KPPLVPTEKD
     SSGPMPFVFL ENFTYDQSAF DSGSHGFIPG PLKNTPHQLG LLAPPNKLQN VLENDYMKSL
     VESPTEETSL IYVSQLASPI CGDKDSLVTN PPMPVHGSEY KKQMALPGSL TSASLKENNL
     TS
//
